Navigation Links
Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

HAYWARD, Calif., Jan. 6, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13, 2011, at approximately 11:00 am Pacific Time.J.P. Morgan Healthcare Conference PresentationDate/Time: Thursday, January 13, at 11:00 am Pacific TimeLocation: Westin St. Francis HotelAbout Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2 or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
4. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Muncie, IN (PRWEB) July 25, 2014 ... Administration (FAA) has granted a 60-day extension for the ... of the Special Rule for Model Aircraft established by ... Act of 2012. The 60-day extension establishes the new ... the United States Department of Transportation/FAA notice published in ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2
... Companies looking to thrive in an increasingly competitive atmosphere are ... on one rather unusual method: speed-networking, a concept based on ... to this story now using RealPlayer , ,Its not ... eat the slow. That phrase was used to kick off ...
... still beaming on Saturday, a day after the Legislatures upper ... and build a stronger in-state network for entrepreneurs , ,Not ... fall, but this is the most important so far to ... with Democrats and Republicans alike in helping to pass the ...
... - EraGen Biosciences , a Wisconsin-based life ... and technologies that accelerate the drug discovery process, ... that it has selected ITOCHU Corporation ... integrated phylogenomics product, Master Catalog , in ...
Cached Biology Technology:Looking to be Competitive? Try Speed Networking 2Senate Passes an Investment Capital Package; the Assembly Should Follow Suit 2Senate Passes an Investment Capital Package; the Assembly Should Follow Suit 3EraGen Expands in Japan 2
(Date:7/25/2014)... Prediabetes and Diabetes increasingly consume the healthcare ... immediate attention. , To address the ... impacting low-and middle-income countries, global leaders in ... research in diabetes prevention and development of ... important text. , This book on ...
(Date:7/25/2014)... tractography (DTT), which is derived from diffusion tensor ... motor tracts, such as the corticospinal tract, the ... The corticospinal tract is known to be a ... human brain. Several studies have reported on injury ... addition, some studies have demonstrated recovery of a ...
(Date:7/25/2014)... detected an unknown interaction between microorganisms and salt. When ... droplet of salt water and is left to dry, ... biosaline 3D morphologically complex formations, where they hibernate. Afterwards, ... discovery was made by chance with a home microscope, ... journal and may help to find signs of ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2Bacteria manipulate salt to build shelters to hibernate 2
... field trials of Miscanthus x giganteus , a towering ... yields, though reduced somewhat after five years of growth, are ... ), another perennial grass used as a bioenergy feedstock. ... yields found in earlier studies of the crop in Europe, ...
... Sciences (AIBS) has selected three individuals as winners of ... This is the third year AIBS has sponsored ... members of the scientific community to showcase for the ... informing natural resources management, addressing climate change, improving human ...
... For some 5,000 years, cultivated silkworms have been spinning ... finest clothing. But current dyeing practices produce wastewater that ... a new, "greener" dyeing method in which they coax ... leaves. Their findings are published in the journal ...
Cached Biology News:The first decade: Team reports on US trials of bioenergy grasses 2The first decade: Team reports on US trials of bioenergy grasses 3AIBS announces winners of Faces of Biology photo competition 2
Lingo-1 (K-13)...
... well-characterized tissue-specific stem cells that exhibit remarkable ... life-long maintenance of the hematopoietic system. HSC ... bone marrow where hematopoiesis is continuously taking ... cord blood, fetal liver, adult spleen and ...
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
Biology Products: